相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The clinical impact of the molecular landscape of acute myeloid leukemia
Sabine Kayser et al.
HAEMATOLOGICA (2023)
Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells
Faruk Sacirbegovic et al.
IMMUNITY (2023)
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Zhuohao Liu et al.
MOLECULAR CANCER (2023)
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Jiao-jiao Ni et al.
ACTA PHARMACOLOGICA SINICA (2023)
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Sham Mailankody et al.
NATURE MEDICINE (2023)
Advancing CAR T cell therapy through the use of multidimensional omics data
Jingwen Yang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Ponatinib and blinatumomab for Philadelphia chromosome- positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
Elias Jabbour et al.
LANCET HAEMATOLOGY (2023)
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
Mingming Zhang et al.
Lancet Haematology (2023)
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Toan D. Nguyen et al.
CANCERS (2023)
Antibody drug conjugates for the treatment of multiple myeloma
Sarah Leong et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
How I treat cytopenias after CAR T-cell therapy
Tania Jain et al.
BLOOD (2023)
How I treat refractory CRS and ICANS after CAR T-cell therapy
Michael D. Jain et al.
BLOOD (2023)
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
Lorenzo Falchi et al.
BLOOD (2023)
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodriguez-Otero et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Yinqiang Zhang et al.
BLOOD CANCER JOURNAL (2023)
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past
Nicholas J. Short et al.
LANCET HAEMATOLOGY (2023)
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
Fengmei Song et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice
Rujul H. Parikh et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis
Youwen Zhu et al.
CANCER (2023)
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
Michael Boyiadzis et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Ming Shi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Tanya Siddiqi et al.
BLOOD (2022)
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
Allison M. Bock et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu et al.
HAEMATOLOGICA (2022)
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Nigel H. Russell et al.
HAEMATOLOGICA (2022)
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A. Jacobson et al.
LANCET ONCOLOGY (2022)
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi et al.
MOLECULAR CANCER (2022)
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
Pingyan Cheng et al.
MOLECULAR THERAPY (2022)
Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells
J. Joseph Melenhorst et al.
NATURE (2022)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler et al.
NATURE MEDICINE (2022)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade
Natalija Budimir et al.
CANCER IMMUNOLOGY RESEARCH (2022)
Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions
Jeanette Wat et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Kathleen M. Mahoney et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
Nico Gagelmann et al.
BLOOD ADVANCES (2022)
Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy
Bryan J. Schneider et al.
JCO ONCOLOGY PRACTICE (2022)
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Dietrich W. Beelen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
S. Horwitz et al.
ANNALS OF ONCOLOGY (2022)
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY (2022)
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
Matthew G. Mei et al.
BLOOD (2022)
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Mingzhi Zhang et al.
CLINICAL CANCER RESEARCH (2022)
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
Karl L. Banta et al.
IMMUNITY (2022)
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Kevin Pan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Post-transplant lymphoproliferative disorder presenting as supraglottitis following pediatric heart transplantation treated with EBV-specific cytotoxic T-lymphocytes
Sophie Duignan et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2022)
Management of Immunotherapy-Related Toxicities, Version 1.2022
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
Gils Roex et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
Deborah A. Katz et al.
LEUKEMIA & LYMPHOMA (2022)
Stepping forward in antibody-drug conjugate development
Yiming Jin et al.
PHARMACOLOGY & THERAPEUTICS (2022)
A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CART cells and gilteritinib
Ke-xin Li et al.
MOLECULAR CANCER (2022)
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu et al.
NATURE MEDICINE (2022)
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+Lymphoma
Wei Sang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji et al.
LANCET HAEMATOLOGY (2022)
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET HAEMATOLOGY (2022)
Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics (vol 23, pg 359, 2021)
Filippos T. Charitidis et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
Elizabeth M. Holland et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
Shih-Cheng Pao et al.
PHARMACEUTICS (2022)
Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials
Yang Xu et al.
CANCER COMMUNICATIONS (2022)
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products
Lipei Shao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Michael J. Dickinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies
Abdullah Freiwan et al.
BLOOD (2022)
CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma
Qian Cheng et al.
CYTOTHERAPY (2022)
CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.
Ravi Vij et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.
Rafael Fonseca et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
Xin Jin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Alison Sehgal et al.
LANCET ONCOLOGY (2022)
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E. Budde et al.
LANCET ONCOLOGY (2022)
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
Heiner Zimmermann et al.
LEUKEMIA (2022)
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction
Penglei Jiang et al.
LEUKEMIA (2022)
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients
Gautam Borthakur et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD
Xiaohui Kong et al.
BLOOD (2022)
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL
Lijun Zhao et al.
BLOOD (2022)
OAB-007: Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma
Noopur Raje et al.
Clinical Lymphoma Myeloma & Leukemia (2022)
MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis
Hang Quach et al.
Clinical Lymphoma Myeloma & Leukemia (2022)
P-017: MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant
María-Victoria Mateos et al.
Clinical Lymphoma Myeloma & Leukemia (2022)
MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Jeffrey A. Zonder et al.
Clinical Lymphoma Myeloma & Leukemia (2022)
In vitro and in vivo evidence that the switch from c for updates calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder
Constantin J. Thieme et al.
KIDNEY INTERNATIONAL (2022)
The journey of CAR-T therapy in hematological malignancies
Junru Lu et al.
MOLECULAR CANCER (2022)
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
Masao Hashimoto et al.
NATURE (2022)
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Jiqin Zhang et al.
NATURE (2022)
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Ben Sprangers et al.
NATURE REVIEWS NEPHROLOGY (2022)
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
Dongni Shi et al.
NATURE COMMUNICATIONS (2022)
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial
Elias Jabbour et al.
LANCET HAEMATOLOGY (2022)
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt et al.
Lancet Haematology (2022)
Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) plus Lenalidomide (Len) Vs Tafa plus Len in Relapsed or Refractory DLBCL
Krish Patel et al.
BLOOD (2022)
MajesTEC-7: A Phase 3, Randomized Study of Teclistamab plus Daratumumab plus Lenalidomide (Tec-DR) Versus Daratumumab plus Lenalidomide plus Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
Amrita Y. Krishnan et al.
BLOOD (2022)
Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma
Ola Landgren et al.
BLOOD (2022)
Chronic GVHD on the move
Antonia M. S. Mueller
BLOOD (2022)
Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+Acute Myeloid Leukemia (AML)
David A. Sallman et al.
BLOOD (2022)
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Sandy W. Wong et al.
BLOOD (2022)
Proteomic and Transcriptomic Profiling Reveals Insights into Mechanisms of Leukemic Immune Escape
Sean Tracy et al.
BLOOD (2022)
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Joseph P. McGuirk et al.
BLOOD (2022)
Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Binod Dhakal et al.
BLOOD (2022)
First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma
Eliza Hawkes et al.
BLOOD (2022)
Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Sanjay R. Mohan et al.
BLOOD (2022)
Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
Emma Searle et al.
BLOOD (2022)
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Krish Patel et al.
BLOOD (2022)
Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma
Christopher J. Ferreri et al.
BLOOD (2022)
Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
Susan Bal et al.
BLOOD (2022)
Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Naval Daver et al.
BLOOD (2022)
Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
Xiao-Tong Zhang et al.
CANCER CELL INTERNATIONAL (2022)
Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective
Xiaohui Si et al.
CANCER LETTERS (2022)
MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
Elena Zamagni et al.
BLOOD (2022)
Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
Sebastian Grosicki et al.
BLOOD (2022)
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu et al.
CELL RESEARCH (2022)
An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
Meijie Tian et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Natural killer cells in antitumour adoptive cell immunotherapy
Tamara J. Laskowski et al.
NATURE REVIEWS CANCER (2022)
A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level
Rita Pfeifer et al.
THERANOSTICS (2022)
Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
Mengyi Du et al.
FRONTIERS IN IMMUNOLOGY (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
Gerald G. Wulf et al.
LEUKEMIA (2021)
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Kristen Fousek et al.
LEUKEMIA (2021)
Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity
Andrea Schmidts et al.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 (2021)
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
Maxime Fayon et al.
HAEMATOLOGICA (2021)
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
M-L Schubert et al.
ANNALS OF ONCOLOGY (2021)
Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
Philippe Armand et al.
LEUKEMIA (2021)
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL
Yaqi Zhao et al.
BLOOD (2021)
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
Erica Brivio et al.
BLOOD (2021)
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma
Hui Liu et al.
CLINICAL CANCER RESEARCH (2021)
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies
Junji Tanaka
HEMATOLOGICAL ONCOLOGY (2021)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Mehdi Hamadani et al.
BLOOD (2021)
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
Di Wang et al.
BLOOD (2021)
Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma
Alexander Lesokhin et al.
BLOOD (2021)
Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)
Guillermo Garcia-Manero et al.
BLOOD (2021)
Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non- Hodgkin's Lymphoma: Initial Clinical Results
Amitkumar Mehta et al.
BLOOD (2021)
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
Lazaros J. Lekakis et al.
BLOOD (2021)
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies
Michael Dickinson et al.
BLOOD (2021)
Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic `Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+B-ALL
Nitin Jain et al.
BLOOD (2021)
A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Shaji Kumar et al.
BLOOD (2021)
Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an AntiCD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Nitin Jain et al.
BLOOD (2021)
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion
Wenli Fang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
Vianihuini Figueroa-Vazquez et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Yao Wang et al.
NATURE COMMUNICATIONS (2021)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D. Santomasso et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
Carlota Gudiol et al.
LANCET HAEMATOLOGY (2021)
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Heng Mei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Zhaoming Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Jochen Buechner et al.
BLOOD ADVANCES (2021)
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
Michael D. Jain et al.
BLOOD (2021)
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2021)
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Patrick A. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Franco Locatelli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Robert J. Kreitman et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla et al.
LANCET ONCOLOGY (2021)
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major et al.
LEUKEMIA & LYMPHOMA (2021)
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
Tracy Rabilloud et al.
NATURE COMMUNICATIONS (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
Jeff P. Sharman et al.
LANCET HAEMATOLOGY (2021)
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer et al.
EUROPEAN JOURNAL OF CANCER (2021)
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Catherine Diefenbach et al.
Lancet Haematology (2021)
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Linda Wu et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
LEMZOPARLIMAB (TJ011133), AN ANTI-CD47 ANTIBODY, WITH/WITHOUT DEXAMETHASONE PLUS ANTI-MYELOMA REGIMENS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PHASE 1B DOSE ESCALATION AND EXPANSION STUDY
Edward Stadtmauer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
Emiliano Roselli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
Ilias Christodoulou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Zheng Tian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F. Caimi et al.
LANCET ONCOLOGY (2021)
Endocrine toxicities of immune checkpoint inhibitors
Jordan J. Wright et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies
Rocio Castellanos-Rueda et al.
TRENDS IN BIOTECHNOLOGY (2021)
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells
Zhiliang Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas
Ross Salvaris et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski et al.
BLOOD (2021)
Characterization of HLH-like manifestations as a CRS variant in CD22 CAR T cells
Daniel A. Lichtenstein et al.
BLOOD (2021)
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao et al.
CANCER RESEARCH (2021)
Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
Zhigang Nian et al.
CLINICAL CANCER RESEARCH (2021)
Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation
Matthew H. Abramson et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+NHL.
Bijal D. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
Jing Pan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Single-cell imaging of T cell immunotherapy
Chuan Yan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Qingya Cui et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani et al.
LANCET (2021)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau et al.
LANCET (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings et al.
LANCET (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
Murat Tekguc et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Exploiting Single-Cell Tools in Gene and Cell Therapy
Daniel Bode et al.
FRONTIERS IN IMMUNOLOGY (2021)
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R. Kelly et al.
LANCET HAEMATOLOGY (2021)
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani et al.
Lancet Haematology (2021)
Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
Rebecca Baur et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions
Ban Qi Tay et al.
VACCINES (2021)
Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma A Systematic Review and Meta-analysis
Jun Du et al.
JAMA NETWORK OPEN (2021)
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
Zhengli Xu et al.
CANCER BIOLOGY & MEDICINE (2021)
Therapeutic cancer vaccines
Mansi Saxena et al.
NATURE REVIEWS CANCER (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis
Amrita Goyal et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Translating gammadelta (gamma delta) T cells and their receptors into cancer cell therapies
Zsolt Sebestyen et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang et al.
CANCER LETTERS (2020)
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress
Sarah A. Holstein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study
Sandra Cohen et al.
LANCET HAEMATOLOGY (2020)
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Elise Fournier et al.
BLOOD (2020)
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
Xin He et al.
BLOOD (2020)
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation
Amanda DeMauro Renaghan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Magid Awadalla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm
Elodie Bole-Richard et al.
LEUKEMIA (2020)
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
George R. Nahas et al.
LEUKEMIA & LYMPHOMA (2020)
An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity
Yik Andy Yeung et al.
MOLECULAR THERAPY (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant
David M. Burns et al.
TRANSPLANTATION (2020)
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Laura Strauss et al.
SCIENCE IMMUNOLOGY (2020)
Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics
Felix Horns et al.
CELL REPORTS (2020)
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Heliang Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
Antonio G. Solimando et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
Kris M. Mahadeo et al.
LANCET HAEMATOLOGY (2020)
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Olaf Penack et al.
Lancet Haematology (2020)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Sham Mailankody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
Ge Qin et al.
NATURE COMMUNICATIONS (2020)
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Samantha R. Ellis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Immune checkpoint inhibitor-related dermatologic adverse events
Amaris N. Geisler et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
Robert David Sandler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation
Francesca Bonifazi et al.
FRONTIERS IN IMMUNOLOGY (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Virginie Grouthier et al.
ONCOLOGIST (2020)
Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study
Feng-Mei Zheng et al.
CANCER COMMUNICATIONS (2020)
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
Craig W. Freyer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Chronic immune checkpoint inhibitor pneumonitis
Jarushka Naidoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
Alejandro Meraz-Munoz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial
Matthew J. Frank et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Sandra M. Herrmann et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status
Yue Lu et al.
ANNALS OF HEMATOLOGY (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Luke Coyle et al.
LEUKEMIA & LYMPHOMA (2020)
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Runxia Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Qing Deng et al.
NATURE MEDICINE (2020)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah et al.
NATURE MEDICINE (2020)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Robin Foa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach et al.
Lancet Haematology (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy
Zhen Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
Immunotherapy for advanced hepatocellular carcinoma, where are we?
Li Zhang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Ahmet Yilmaz et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Anti-tumour immunity induces aberrant peptide presentation in melanoma
Osnat Bartok et al.
NATURE (2020)
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Sri Krishna et al.
SCIENCE (2020)
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Xuan Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases
Sandra Tong et al.
BLOOD (2020)
A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results
Junyuan Qi et al.
BLOOD (2020)
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Carlos Bachier et al.
BLOOD (2020)
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Simon J. Harrison et al.
BLOOD (2020)
Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
Shaji K. Kumar et al.
BLOOD (2020)
Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Alexander M. Lesokhin et al.
BLOOD (2020)
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma
Xinfeng Chen et al.
IMMUNOTHERAPY (2020)
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
Roberta Sommaggio et al.
ONCOIMMUNOLOGY (2020)
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome
Marte B. Kammersgaard et al.
BONE MARROW TRANSPLANTATION (2019)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Christina L. Zuch de Zafra et al.
CLINICAL CANCER RESEARCH (2019)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma
Ken Ohmachi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity
Marine Cazaux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Herve Tilly et al.
LANCET ONCOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts
Luke Jones et al.
PEDIATRIC BLOOD & CANCER (2019)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Phage display screening of therapeutic peptide for cancer targeting and therapy
Phei Er Saw et al.
PROTEIN & CELL (2019)
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
Jeroen M. K. de Filette et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis
Pieter Fokko van Loo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies
Sunita Nathan et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient
Elizabeth Ann Misch et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient
Lauren Fontana et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11
Johannes Duell et al.
JOURNAL OF IMMUNOTHERAPY (2019)
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
Vivek Verma et al.
NATURE IMMUNOLOGY (2019)
Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial
Huiwen Jiang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Ute F. Rohrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Management of cytokine release syndrome related to CAR-T cell therapy
Hongli Chen et al.
FRONTIERS OF MEDICINE (2019)
Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
Caitlin L. Costello et al.
BLOOD (2019)
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
Xiao Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan et al.
LANCET HAEMATOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Myriam Delaunay et al.
EUROPEAN RESPIRATORY REVIEW (2019)
Diagnosis of Hodgkin lymphoma in the modern era
Hao-Wei Wang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Anna Wolska-Washer et al.
DRUG SAFETY (2019)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients
Andre Tichelli et al.
JAMA ONCOLOGY (2019)
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
Rebecca Karp Leaf et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Cleavable linkers in antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SOCIETY REVIEWS (2019)
Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?
Xiao-Su Zhao et al.
BIOMARKER RESEARCH (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Hypogammaglobulinemia due to CAR T-cell therapy
Michael A. Pulsipher
PEDIATRIC BLOOD & CANCER (2018)
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Yu Ping et al.
PROTEIN & CELL (2018)
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (vol 23, pg 2356, 2012)
M. S. Czuczman et al.
ANNALS OF ONCOLOGY (2018)
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
W. Jurczak et al.
ANNALS OF ONCOLOGY (2018)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
Bispecific antibodies in haematological malignancies
Andreas Viardot et al.
CANCER TREATMENT REVIEWS (2018)
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
Olivia Campagne et al.
CLINICAL CANCER RESEARCH (2018)
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Anastasios Stathis et al.
INVESTIGATIONAL NEW DRUGS (2018)
Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
Joshua Ryan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
John A. Thompson
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Yoh Zen et al.
MODERN PATHOLOGY (2018)
IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Yelena Kovtun et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
Exponential scaling of single-cell RNA-seq in the past decade
Valentine Svensson et al.
NATURE PROTOCOLS (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management
Mark A. Samaan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Kerry Reynolds et al.
ONCOLOGIST (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial
Elias Jabbour et al.
JAMA ONCOLOGY (2018)
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
Amir T. Fathi et al.
BLOOD (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Noelle Frey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Monika Herrmann et al.
BLOOD (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel et al.
LANCET ONCOLOGY (2018)
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Verena Staedtke et al.
NATURE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Improving Immunotherapy Through Glycodesign
Matthew J. Buettner et al.
FRONTIERS IN IMMUNOLOGY (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H. Geukes Foppen et al.
ESMO OPEN (2018)
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Farhad Ravandi et al.
BLOOD (2018)
Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma
Thorsten Ross et al.
BLOOD (2018)
Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Jorge E. Cortes et al.
BLOOD (2018)
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu et al.
NATURE REVIEWS IMMUNOLOGY (2018)
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
Nicholas J. Short et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Peter G. Maslak et al.
BLOOD ADVANCES (2018)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Joshua A. Hill et al.
BLOOD (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez et al.
BLOOD (2018)
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Renal dysfunction following bone marrow transplantation
Stephan Kemmner et al.
JOURNAL OF NEPHROLOGY (2017)
Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?
Mahasweta Gooptu et al.
HAEMATOLOGICA (2017)
Improved survival after acute graft-versus-host disease diagnosis in the modern era
Hanna J. Khoury et al.
HAEMATOLOGICA (2017)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Immunotherapy in hematologic malignancies: past, present, and future
Annie Im et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Single-cell transcriptomics to explore the immune system in health and disease
Michael J. T. Stubbington et al.
SCIENCE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?
Mahasweta Gooptu et al.
HAEMATOLOGICA (2017)
Improved survival after acute graft-versus-host disease diagnosis in the modern era
Hanna J. Khoury et al.
HAEMATOLOGICA (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Reid W. Merryman et al.
BLOOD ADVANCES (2017)
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
M. Collins et al.
ANNALS OF ONCOLOGY (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Inotuzumab Ozogamicin: First Global Approval
Yvette N. Lamb
DRUGS (2017)
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia
Ibrahim Aldoss et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani et al.
BLOOD (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Lakshmi Nayak et al.
BLOOD (2017)
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
Kevin A. Hay et al.
DRUGS (2017)
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
Modern approaches to HLA-haploidentical blood or marrow transplantation
Christopher G. Kanakry et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
Guillaume Olombel et al.
BLOOD (2016)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch et al.
CLINICAL CANCER RESEARCH (2016)
Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study
Yu Wang et al.
CLINICAL CANCER RESEARCH (2016)
Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Xenia A. Glukhova et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation
Ying-Jun Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia
Jinichi Mori et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics
Martin Felices et al.
BLOOD (2016)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea et al.
BLOOD (2015)
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study
Yu Wang et al.
BLOOD (2015)
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo
Thomas R. W. Tipton et al.
BLOOD (2015)
Immune checkpoint blockade in hematologic malignancies
Philippe Armand
BLOOD (2015)
How I treat hemophagocytic lymphohistiocytosis in the adult patient
Alison M. Schram et al.
BLOOD (2015)
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
Frauke M. Schnorfeil et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen et al.
LANCET (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad et al.
LEUKEMIA & LYMPHOMA (2015)
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Uwe Reusch et al.
MABS (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Hodgkin Lymphoma: Diagnosis and Treatment
Stephen M. Ansell
MAYO CLINIC PROCEEDINGS (2015)
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Daniel S. Pereira et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
Tao Dao et al.
NATURE BIOTECHNOLOGY (2015)
Erratum: Modern approaches to HLA-haploidentical blood or marrow transplantation.
Christopher G. Kanakry et al.
Nature Reviews Clinical Oncology (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy
A. S. Nelson et al.
LEUKEMIA (2015)
Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
Kristen N. Ganjoo et al.
LEUKEMIA & LYMPHOMA (2015)
Haematological malignancies: at the forefront of immunotherapeutic innovation
Pavan Bachireddy et al.
NATURE REVIEWS CANCER (2015)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene
Xiaoou Zhou et al.
BLOOD (2014)
The biology of graft-versus-host disease: experimental systems instructing clinical practice
Kate A. Markey et al.
BLOOD (2014)
HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse
Massimo F. Martelli et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line
Mitchell R. Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia
Daniel S. Pereira et al.
CANCER RESEARCH (2014)
A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag et al.
CLINICAL CANCER RESEARCH (2014)
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Alan S. Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody- dependent cell- mediated cytotoxicity in chronic lymphocytic leukemia
Carolyn M. Cheney et al.
MABS (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The tumour microenvironment in B cell lymphomas
David W. Scott et al.
NATURE REVIEWS CANCER (2014)
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults
Udo Holtick et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia
Andrea Pession et al.
BLOOD (2013)
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
John Radford et al.
BLOOD (2013)
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz et al.
BLOOD (2013)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation
Fiona L. Dignan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Hernan Carol et al.
CLINICAL CANCER RESEARCH (2013)
Deciphering and Reversing Tumor Immune Suppression
Greg T. Motz et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group
Cornelia Eckert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
Gilles A. Salles et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
Franck Andre Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers
Serengulam V. Govindan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
M. Aigner et al.
LEUKEMIA (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses
Brian A. Baldo
ONCOIMMUNOLOGY (2013)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
Henrik Hasle et al.
BLOOD (2012)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres et al.
CLINICAL CANCER RESEARCH (2012)
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe et al.
LANCET ONCOLOGY (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Cor H. J. Lamers et al.
BLOOD (2011)
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
Lapo Alinari et al.
BLOOD (2011)
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia
John Schindler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Hybridoma technologies for antibody production
Masahiro Tomita et al.
IMMUNOTHERAPY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
Kajsa Wing et al.
TRENDS IN IMMUNOLOGY (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells
Erin Hertlein et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Bob Lowenberg et al.
BLOOD (2010)
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
E. LEGOUFFE et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne et al.
CLINICAL CANCER RESEARCH (2010)
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
Mohamad Hussein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
Viggo F. Van Tendeloo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey et al.
BLOOD (2009)
Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation
Corey Smith et al.
BLOOD (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2009)
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
A. Cortelezzi et al.
LEUKEMIA (2009)
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience
Paolo Anderlini et al.
HAEMATOLOGICA (2008)
Immunoglobulin Replacement Therapy in Children
Maria Garcia-Lloret et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel et al.
NATURE (2007)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Isolating and engineering human antibodies using yeast surface display
Ginger Chao et al.
NATURE PROTOCOLS (2006)
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
SS Neelapu et al.
NATURE MEDICINE (2005)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
T-cell activation by recombinant immunoreceptors:: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells
C Heuser et al.
GENE THERAPY (2003)
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
Y Oka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Autologous transplantation for aggressive non-hodgkin's lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens
H Bertz et al.
ANNALS OF ONCOLOGY (2002)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)